The FDA has initiated a new Commissioner’s Priority Voucher Program aimed at expediting drug reviews, allowing for approval times to be reduced to as little as two months. This program is designed to support drug developers whose projects align with U.S. national interests. In addition, the agency plans to integrate artificial intelligence into the drug approval process to increase efficiency and ensure faster decision-making. FDA officials have outlined their vision for a reimagined agency that will not only shorten review timelines but also enhance safety protocols through innovative technology. As part of these changes, the FDA is committed to fostering a more collaborative environment with biopharmaceutical companies, allowing for quicker access to crucial medications.